Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2017-10-26 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Pharnext's drug PXT3003 will be featured at an upcoming Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit. It details the presentation times, titles, and presenters, and provides background information on the drug, the foundation, and the company. This is not a formal regulatory filing like a 10-K, IR, or ER. It is an announcement about participation in an industry/patient event, which often falls under general investor relations or regulatory communication. Since it is an announcement about company activity and participation in an external event, and it doesn't fit the specific categories like AGM-R, ER, or CT, the most appropriate general category for non-standard regulatory/investor news is Regulatory Filings (RNS), which serves as a broad category for miscellaneous announcements not covered elsewhere.
2017-10-26 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release ("Communiqué de presse") dated October 26, 2017, announcing that Pharnext will present data on its drug candidate PXT3003 at an upcoming patient-focused annual congress organized by the Hereditary Neuropathy Foundation (HNF) on November 3rd. It details the oral and poster sessions where clinical trial updates will be shared. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about participation in an external medical/patient event where company data will be presented. This type of announcement, which details upcoming presentations of clinical or research data, most closely aligns with an Investor Presentation (IP) if it were the presentation itself, but since it is an announcement *about* presenting data at a conference, it falls under general corporate communication regarding investor/research updates. Given the options, it is a specific announcement about data presentation, which is often grouped with Investor Presentations (IP) or sometimes general Regulatory Filings (RNS) if no better fit exists. However, since it details specific sessions and data updates intended for investors and the medical community, 'Investor Presentation' (IP) is the closest fit for the *content* being discussed, even though this specific document is the announcement of that presentation. Since it is a press release detailing scientific/clinical updates intended for investors, IP is the most appropriate classification among the choices, as it relates directly to presenting company progress to the investment community.
2017-10-26 French
First-Half 2017
Earnings Release Classification · 1% confidence The document explicitly states it is announcing the 'First-Half 2017' financial results. It includes a summary table of H1 2017 vs H1 2016 financial figures (Operating income, Net income, Cash flows) and discusses the financial implications of recent agreements. This content strongly aligns with an Earnings Release (ER), which is the initial announcement of periodical financial results, often presented as a press release summarizing key figures. Although it mentions the half-year financial report is available on the website, the document itself is the announcement/release of those results, not the comprehensive report (which would be an IR). Since it focuses on period results and key highlights rather than being a general regulatory filing or a full transcript, ER is the most appropriate classification. H1 2017
2017-10-19 English
Pharnext to Present at 4th International Neurotech Investing and Partnering Conference
Regulatory Filings Classification · 1% confidence The document is a short news release dated September 28, 2017, announcing that Pharnext management will present at the '4th International Neurotech Investing and Partnering Conference' on October 4, 2017. It provides details about the presentation time and venue, and includes boilerplate information about the company and contacts. Since this is an announcement about participation in an external conference, and not a formal regulatory filing like a 10-K, ER, or IR, it best fits the category for general corporate news or announcements that don't fit elsewhere. Given the context of presenting corporate overview and strategy to investors at a conference, it is most closely related to Investor Presentation (IP) materials, but the document itself is just the *announcement* of the presentation, not the presentation slides or the full report. Following Rule 2 (Menu vs Meal), if the document is short and announces an event or report, it leans towards a general announcement. Since it is specifically about presenting corporate information to investors at a conference, it is a strong candidate for Investor Presentation (IP) if the content were the slides, but as an announcement of attendance, it is a general corporate news item. However, looking at the definitions, 'Investor Presentation (IP)' is for the detailed presentation itself. This is an announcement of management presenting. The closest fit among the options for an announcement about management communicating strategy/overview to investors at a conference is often categorized under general investor relations activity. Since there isn't a specific 'Conference Presentation Announcement' code, and it's not a formal regulatory filing, it falls under the general regulatory/news announcement category, RNS, as a fallback for corporate news that doesn't fit the specific financial report types. However, given the content is explicitly about presenting corporate information to investors, it is highly related to investor communication. If we must choose the most specific category related to the *topic* being presented, it relates to the company's strategy and pipeline, which is often covered in an IP. But strictly applying Rule 2, this is an announcement of an event, not the event material itself. Therefore, RNS (Regulatory Filings / General Announcement) is the safest fallback for this type of news release.
2017-09-28 English
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that company management will present a corporate overview at an external investment conference (4th International Neurotech Investing and Partnering Conference). This type of announcement, detailing participation in investor events, is typically classified as Investor Presentation (IP) material or an announcement thereof. However, since the document itself is an announcement about *attending* an event where a presentation will be given, and it is not the presentation slides themselves, it fits best under the general category for investor communications or announcements related to investor engagement. Given the options, this is a communication aimed at investors about future engagement, which is closely related to Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a specific announcement about management presenting corporate information to investors, 'Investor Presentation (IP)' is the most fitting specific category, even though it's the announcement rather than the slides. If the document were purely a notice about a report release, RPA would apply, but this is about an event appearance. I will classify it as IP as it pertains directly to management presenting company information to investors.
2017-09-28 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that the management team of Pharnext will be presenting at the '4th International Neurotech Investing and Partnering Conference' on October 4, 2017. This announcement is specifically about the company's participation in an external investor/partnering event where they will present their activities and pipeline. This aligns best with the 'Investor Presentation' (IP) category, as the core purpose is to present company information to investors, even if the presentation itself is happening externally. It is not a formal regulatory filing (like 10-K or IR), nor is it a transcript (CT) or a general earnings release (ER). It is an announcement about an upcoming presentation to investors.
2017-09-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.